Gab Angelini (Bank of America) asked why strategic and sponsor M&A have diverged year-to-date and the outlook for sponsor activity, plus the key Asset Management changes and KPIs.
Peter Orszag attributed the divergence to a valuation gap from higher rates that discourages sponsors from selling, offset by building LP distribution pressure (an accelerant for secondaries/continuation funds where Lazard/Campbell Lutyens is well-positioned); Chris Hogbin cited a new CIO and COO, AI adoption, 68% of AUM beating five-year benchmarks, and $7.5B of H1 net inflows as trackable progress.
Brennan Hawken (BMO) asked for color on the more pronounced second-half advisory seasonality and on the quarter-over-quarter decline in MD headcount.
Tracy Farr said the lighter first half and the pace of pipeline build make the usual 2H-over-1H strength more pronounced this year; Orszag said to ignore quarterly MD fluctuations (garden-leave/separation timing), with tenured MDs set to more than triple from 2023 to 2028 and ramping disproportionately in healthcare, industrials, technology, and private capital.
Mike Brown (UBS) asked about second-half Asset Management flow puts and takes and whether the strong first half can continue, plus whether FA can drive the comp ratio to ~65.5%.
Hogbin cited broad product and geographic breadth (Advantage doubled to $50B, EM, infrastructure, Japan, fixed income) and a won-but-not-funded pipeline above year-end, with retail steady and institutional lumpier; Farr said the comp ratio is indexed to second-half FA performance and could improve, without committing to a level.
James Yaro (Goldman Sachs) asked how AI can benefit Lazard's strategic advisory and secondaries, and whether anything (pull-forwards) changed the strong quarter.
Orszag pointed to matching strategics with private/insurance capital, a rich GP/LP data asset from the Lazard CL combination, and AI deployment to banking/AM teams; he said there were no exceptional pull-forwards, just increasing momentum as the firm emerges from the J-curve.
Connell Schmitz (Morgan Stanley) asked about the Claude rollout and AI strategy, non-comp expense trajectory, and corporate-overhead reduction progress.
Orszag framed Claude as consistent with a deliberate multi-model, no-single-source strategy focused on cultural change, with spend still immaterial; Farr described efficiency work (smaller deal teams, AM headcount reductions, a back-office review) aimed at sticky structural change that decouples corporate-cost growth from revenue.
Steven Chubak (Wolfe Research) asked about the comp trajectory beyond 2026 and momentum in the non-M&A businesses.
Orszag and Farr described three forces driving a significant comp-ratio decline in 2027-2028 (fading one-time buyout/amortization costs, operating leverage on rising per-MD productivity, and direct efficiencies), with the revenue tailwind arriving in 2027 and comp normalizing by 2028; non-M&A (PCA, restructuring/liability management) is trending healthily and will expand with Lazard CL.
Devin Ryan (Citizens JMP) asked what is driving the acceleration in $5 billion-plus conflict clearances.
Orszag clarified the >100% figure is fee-weighted and attributed the large-cap uplift to three things: a market skewed toward large strategic deals, a deliberate leadership initiative to raise league-table and large-cap prominence, and Lazard's talent plus 'contextual alpha' (incorporating geopolitics) winning more boardroom access.
Alex Bond (KBW) asked whether the sub-$5 billion deal cohort is picking up and whether the mid-to-high-single-digit non-comp growth guide still holds.
Orszag said a sub-$5B pickup largely depends on private equity reawakening (forward indicators are strong despite subdued sponsor activity); Farr confirmed non-comp growth guidance holds (maybe up a point or two, with some Campbell Lutyens noise), AI spend rising but immaterial, and higher client-convening travel viewed as a revenue driver offset by other savings.